Gujarat Themis BiosynBOM:506879 -2.40%76 ROA % is 8.65% as of Mar. 2026, which is 68% below its 10-year median of 27.40. GuruFocus rates BOM:506879 with a GF Score™ of 76/100 and a GF Value™ of ₹313.05 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Gujarat Themis Biosyn ranks better than 87.74% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Gujarat Themis Biosyn's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹436 Mil.
Gujarat Themis Biosyn's average Total Assets over the quarter that ended in Mar. 2026 was ₹5,034 Mil. Therefore, Gujarat Themis Biosyn's annualized ROA % for the quarter that ended in Mar. 2026 was 8.65%.
The historical rank and industry rank for Gujarat Themis Biosyn's ROA % or its related term are showing as below:
BOM:506879'
s ROA % Range Over the Past 10 Years
Min: 11.6 Med: 27.4 Max: 48.9
Current: 11.85
During the past 13 years, Gujarat Themis Biosyn's highest ROA % was 48.90%. The lowest was 11.60%. And the median was 27.40%.
BOM:506879's ROA % is ranked better than 87.74% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs BOM:506879: 11.85
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Themis Biosyn's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Themis Biosyn ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gujarat Themis Biosyn's ROA % distribution charts can be found below:
* The bar in red indicates where Gujarat Themis Biosyn's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Gujarat Themis Biosyn (BOM:506879) has a ROA % of 8.65% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Gujarat Themis Biosyn and its competitors. This is 68% below median its historical median of 27.40. Over the past decade, Gujarat Themis Biosyn's ROA % has ranged from 11.60 to 48.90. According to the industry distribution chart, Gujarat Themis Biosyn ranks #123 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 12.3%.
Is Gujarat Themis Biosyn's ROA % too high?
Gujarat Themis Biosyn's current ROA % of 8.65% is 68% below median its 10-year median of 27.40. Over the past 10 years, this metric has ranged from a low of 11.60 to a high of 48.90. The Drug Manufacturers industry median ROA % is 2.72. Gujarat Themis Biosyn's value of 8.65% is 218% above this industry median. Based on the distribution chart, Gujarat Themis Biosyn ranks #123 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gujarat Themis Biosyn has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gujarat Themis Biosyn's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gujarat Themis Biosyn ranks #123 out of 1003 companies for ROA %. This places Gujarat Themis Biosyn in the top 12% of its industry — outperforming the majority of peers. The industry median ROA % is 2.72. Gujarat Themis Biosyn's value of 8.65% is 218% above this benchmark. Historically, Gujarat Themis Biosyn's own ROA % has ranged from 11.60 to 48.90 over the past decade. While the company's 10-year median is 27.40 vs. the industry median of 2.72, Gujarat Themis Biosyn has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Themis Biosyn's current ROA % of 8.65% is 218% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Gujarat Themis Biosyn and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Themis Biosyn's current ROA % is 8.65%, which is 68% below median its own 10-year median of 27.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Themis Biosyn stock overvalued right now?
Based on GuruFocus' analysis, Gujarat Themis Biosyn (BOM:506879) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹313.05, compared to a current price of ₹386.30 — trading 23.4% above its estimated fair value. The current ROA % is 8.65%, which is 68% below median its 10-year median of 27.40 and 218% above the Drug Manufacturers industry median of 2.72. Gujarat Themis Biosyn's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Gujarat Themis Biosyn (BOM:506879), the current ROA % is 8.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gujarat Themis Biosyn (BOM:506879) Overvalued in 2026?
Based on GuruFocus' analysis, Gujarat Themis Biosyn stock appears to be overvalued.
The current stock price of ₹386.30 is trading 23.4% above its estimated GF Value™ of ₹313.05.
GuruFocus considers Gujarat Themis Biosyn to be Modestly Overvalued.
Key valuation signals for BOM:506879:
ROA %: 8.65% (68% below median its 10-year median of 27.40)
GF Value™: ₹313.05 vs. price of ₹386.30 (23.4% above fair value)
Industry Position: 218% above the Drug Manufacturers median (#123 of 1003)
No single metric tells the full story. See the BOM:506879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
76GF Score
Get the complete analysis for BOM:506879
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506879 has been successfully added to your 
